Trospium Chloride Tablet, Film Coated
Product Images NDC 71610-812

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 71610-812). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 01)

Chemical structure of Trospium Chloride, the active ingredient of the drug Trospium Chloride 20 mg film-coated tablets by Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Figure 1 (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 02)

A plasma concentration versus time post-dose graph showing the pharmacokinetic profile of Trospium Chloride. The y-axis represents plasma concentration in ng/mL and the x-axis denotes time in hours after dosing, with data points declining over 48 hours indicating drug concentration decrease in plasma.*

FDA Label Image

Figure 2 (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 03)

A line graph comparing mean change over 12 weeks of treatment between placebo and Trospium Chloride groups, with error bars representing standard error. The graph shows mean values at weeks 1, 4, and 12, indicating a greater decrease in the Trospium Chloride group. Statistical significance is noted at p=0.051, p<0.001, and p<0.001 respectively. The sample sizes are 256 for placebo and 253 for Trospium Chloride.*

FDA Label Image

Figure 3 (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 04)

A line graph showing mean change with standard error over 12 weeks of treatment comparing Trospium Chloride and placebo groups. The x-axis represents weeks of treatment (1, 4, 12), and the y-axis shows mean change values. Trospium Chloride group demonstrates a greater decrease over time compared to placebo, with statistical significance noted at weeks 4 (p=0.003) and 12 (p=0.012).*

FDA Label Image

Figure 4 (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 05)

A line graph comparing the mean change over weeks of treatment between placebo and Trospium Chloride groups. The x-axis represents week of treatment (1, 4, 12), and the y-axis shows mean (± SE) change with values decreasing from 0 to -3. Trospium Chloride group shows a greater decrease than placebo across weeks with statistically significant p-values noted.*

FDA Label Image

Figure 5 (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 06)

A line graph comparing the mean change (± SE) over 12 weeks of treatment between placebo and Trospium Chloride groups. The y-axis shows mean change, and the x-axis shows weeks of treatment (1, 4, 12). The Trospium Chloride group shows a consistently greater mean change than placebo, with statistical significance indicated (p<0.001) at all time points.*

FDA Label Image

Image (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 07)

FDA Label Image

Image (0f16a8b8 Be7f 41e6 A5ca C97aba610d43 08)

FDA Label Image

Label (71610 812 87)

Trospium Chloride 20 mg film-coated tablets label showing 2400 tablets per container. The label includes storage instructions to keep the product at 20-25 degrees Celsius, protect from light, and keep out of reach of children. Manufactured by Major Pharmaceuticals in Livonia, MI, and distributed by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label contains the NDC number 71610-812-87.*

FDA Label Image

Aphena (Aphena)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.